OABI
OmniAb, Inc.
Biotechnology
Market Cap$167M
5Y Perf.-84.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OABI vs ADCT vs RCUS vs HALO
Revenue, margins, valuation, and 5-year total return — side by side.
ADCT
ADC Therapeutics S.A.
Biotechnology
Market Cap$478M
5Y Perf.-86.2%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-28.9%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+60.3%
OABI vs ADCT vs RCUS vs HALO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OABI | ADCT | RCUS | HALO |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $167M | $478M | $2.50B | $7.68B |
| Revenue (TTM) | $29M | $79M | $236M | $1.40B |
| Net Income (TTM) | $-54M | $-137M | $-369M | $317M |
| Gross Margin | 82.8% | 90.7% | 90.7% | 81.9% |
| Operating Margin | -173.0% | -149.6% | -168.6% | 58.4% |
| Forward P/E | — | — | — | 8.1x |
| Total Debt | $20M | $439M | $99M | $0.00 |
| Cash & Equiv. | $26M | $261M | $222M | $134M |
OABI vs ADCT vs RCUS vs HALO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OABI
ADCT
RCUS
HALO
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| OmniAb, Inc. (OABI) | 100 | 15.1 | -84.9% |
| ADC Therapeutics S.… (ADCT) | 100 | 13.8 | -86.2% |
| Arcus Biosciences, … (RCUS) | 100 | 71.1 | -28.9% |
| Halozyme Therapeuti… (HALO) | 100 | 160.3 | +60.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OABI vs ADCT vs RCUS vs HALO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arcus Biosciences, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OABI
OmniAb, Inc.
The Specific-Use Pick
OABI plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ADCT
ADC Therapeutics S.A.
The Growth Play
ADCT is the clearest fit if your priority is growth exposure.
- Rev growth 14.9%, EPS growth 30.9%, 3Y rev CAGR -27.1%
Best for: growth exposure
RCUS
Arcus Biosciences, Inc.
The Momentum Pick
RCUS is the #2 pick in this set and the best alternative if momentum is your priority.
- +209.6% vs HALO's -7.1%
Best for: momentum
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.56
- 5.7% 10Y total return vs RCUS's 45.9%
- Lower volatility, beta 0.56, current ratio 4.66x
- Beta 0.56, current ratio 4.66x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HALO | 37.6% revenue growth vs OABI's -29.3% |
| Quality / Margins | HALO | 22.7% margin vs OABI's -187.6% |
| Stability / Safety | HALO | Beta 0.56 vs RCUS's 1.95 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs HALO's -7.1% |
| Efficiency (ROA) | HALO | 12.5% ROA vs ADCT's -44.7% |
OABI vs ADCT vs RCUS vs HALO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
OABI vs ADCT vs RCUS vs HALO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGRCUS
Who Leads Where
HALO leads in 3 of 6 categories
OABI leads 0 • ADCT leads 0 • RCUS leads 0 • 2 tied
Explore the data ↓RCUSArcus Biosciences, In…
0leads
ADCTADC Therapeutics S.A.
0leads
OABIOmniAb, Inc.
0leads
HALOHalozyme Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs OABIvs ADCTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
HALO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO is the larger business by revenue, generating $1.4B annually — 48.3x OABI's $29M. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to OABI's -187.6%. On growth, OABI holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OABIOmniAb, Inc. | ADCTADC Therapeutics … | RCUSArcus Biosciences… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $79M | $236M | $1.4B |
| EBITDAEarnings before interest/tax | -$33M | -$117M | -$391M | $945M |
| Net IncomeAfter-tax profit | -$54M | -$137M | -$369M | $317M |
| Free Cash FlowCash after capex | -$26M | -$115M | -$489M | $645M |
| Gross MarginGross profit ÷ Revenue | +82.8% | +90.7% | +90.7% | +81.9% |
| Operating MarginEBIT ÷ Revenue | -173.0% | -149.6% | -168.6% | +58.4% |
| Net MarginNet income ÷ Revenue | -187.6% | -173.0% | -156.4% | +22.7% |
| FCF MarginFCF ÷ Revenue | -89.9% | -144.7% | -2.1% | +46.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | -9.5% | -39.3% | +51.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +64.7% | +41.7% | +10.5% | -2.1% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — OABI and RCUS and HALO each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | OABIOmniAb, Inc. | ADCTADC Therapeutics … | RCUSArcus Biosciences… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Market CapShares × price | $167M | $478M | $2.5B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $162M | $656M | $2.4B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -2.58x | -3.36x | -7.54x | 25.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 8.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.11x |
| EV / EBITDAEnterprise value multiple | — | — | — | 8.34x |
| Price / SalesMarket cap ÷ Revenue | 8.96x | 5.88x | 10.11x | 5.50x |
| Price / BookPrice ÷ Book value/share | 0.63x | — | 4.22x | 165.47x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 11.91x |
Evenly matched — OABI and RCUS and HALO each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-69 for RCUS. OABI carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), HALO scores 5/9 vs RCUS's 0/9, reflecting solid financial health.
| Metric | OABIOmniAb, Inc. | ADCTADC Therapeutics … | RCUSArcus Biosciences… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -20.3% | — | -69.0% | +6.5% |
| ROA (TTM)Return on assets | -18.1% | -44.7% | -35.3% | +12.5% |
| ROICReturn on invested capital | -19.7% | — | -64.1% | +73.4% |
| ROCEReturn on capital employed | -24.0% | -43.8% | -42.1% | +38.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 0 | 5 |
| Debt / EquityFinancial leverage | 0.08x | — | 0.16x | — |
| Net DebtTotal debt minus cash | -$5M | $178M | -$123M | -$134M |
| Cash & Equiv.Liquid assets | $26M | $261M | $222M | $134M |
| Total DebtShort + long-term debt | $20M | $439M | $99M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -1.72x | -13.38x | 46.08x |
HALO leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
HALO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HALO five years ago would be worth $13,704 today (with dividends reinvested), compared to $1,506 for OABI. Over the past 12 months, RCUS leads with a +209.6% total return vs HALO's -7.1%. The 3-year compound annual growth rate (CAGR) favors HALO at 29.1% vs OABI's -24.8% — a key indicator of consistent wealth creation.
| Metric | OABIOmniAb, Inc. | ADCTADC Therapeutics … | RCUSArcus Biosciences… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -21.8% | +6.8% | +6.5% | -7.3% |
| 1-Year ReturnPast 12 months | -3.9% | +196.1% | +209.6% | -7.1% |
| 3-Year ReturnCumulative with dividends | -57.4% | +77.4% | +24.9% | +115.3% |
| 5-Year ReturnCumulative with dividends | -84.9% | -84.1% | -18.6% | +37.0% |
| 10-Year ReturnCumulative with dividends | -84.9% | -87.3% | +45.9% | +570.7% |
| CAGR (3Y)Annualised 3-year return | -24.8% | +21.0% | +7.7% | +29.1% |
HALO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RCUS and HALO each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than RCUS's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 86.3% from its 52-week high vs OABI's 63.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OABIOmniAb, Inc. | ADCTADC Therapeutics … | RCUSArcus Biosciences… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.51x | 1.89x | 1.95x | 0.56x |
| 52-Week HighHighest price in past year | $2.30 | $4.97 | $28.72 | $82.22 |
| 52-Week LowLowest price in past year | $1.22 | $1.23 | $7.06 | $47.50 |
| % of 52W HighCurrent price vs 52-week peak | +63.9% | +75.7% | +86.3% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 42.5 | 48.0 | 60.5 | 52.4 |
| Avg Volume (50D)Average daily shares traded | 428K | 946K | 1.2M | 1.4M |
Evenly matched — RCUS and HALO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OABI as "Buy", ADCT as "Buy", RCUS as "Buy", HALO as "Buy". Consensus price targets imply 172.1% upside for OABI (target: $4) vs 20.2% for HALO (target: $78).
| Metric | OABIOmniAb, Inc. | ADCTADC Therapeutics … | RCUSArcus Biosciences… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $7.50 | $30.00 | $78.33 |
| # AnalystsCovering analysts | 9 | 12 | 18 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 3 of 6 categories
Loading custom metrics...
OABI vs ADCT vs RCUS vs HALO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is OABI or ADCT or RCUS or HALO a better buy right now?
For growth investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -29. 3% for OmniAb, Inc. (OABI). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate OmniAb, Inc. (OABI) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OABI or ADCT or RCUS or HALO?
Over the past 5 years, Halozyme Therapeutics, Inc.
(HALO) delivered a total return of +37. 0%, compared to -84. 9% for OmniAb, Inc. (OABI). Over 10 years, the gap is even starker: HALO returned +570. 7% versus ADCT's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OABI or ADCT or RCUS or HALO?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 250% more volatile than HALO relative to the S&P 500. On balance sheet safety, OmniAb, Inc. (OABI) carries a lower debt/equity ratio of 8% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OABI or ADCT or RCUS or HALO?
By revenue growth (latest reported year), Halozyme Therapeutics, Inc.
(HALO) is pulling ahead at 37. 6% versus -29. 3% for OmniAb, Inc. (OABI). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OABI or ADCT or RCUS or HALO?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -347. 0% for OmniAb, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -383. 1% for OABI. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OABI or ADCT or RCUS or HALO more undervalued right now?
Analyst consensus price targets imply the most upside for OABI: 172.
1% to $4. 00.
07Which pays a better dividend — OABI or ADCT or RCUS or HALO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is OABI or ADCT or RCUS or HALO better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). ADC Therapeutics S. A. (ADCT) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, ADCT: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OABI and ADCT and RCUS and HALO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OABI is a small-cap quality compounder stock; ADCT is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(OABI: 247.3% · ADCT: -9.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.